Lymphatic transport system to circumvent hepatic metabolism for oral delivery of lipid-based nanocarriers

2021 ◽  
pp. 102934
Author(s):  
Amarjitsing Rajput ◽  
Prashant Pingale ◽  
Darshan Telange ◽  
Shailesh Chalikwar ◽  
Vivek Borse
Keyword(s):  
Transport System ◽  
Oral Delivery ◽  
Hepatic Metabolism ◽  
Lymphatic Transport

Phase‐Changeable Nanoemulsions for Oral Delivery of a Therapeutic Peptide: Toward Targeting the Pancreas for Antidiabetic Treatments Using Lymphatic Transport

2019 ◽  
Vol 29 (13) ◽  
pp. 1809015 ◽  
Author(s):  
Po‐Yen Lin ◽  
Kuan‐Hung Chen ◽  
Yang‐Bao Miao ◽  
Hsin‐Lung Chen ◽  
Kun‐Ju Lin ◽  
...  
Keyword(s):  
Oral Delivery ◽  
Lymphatic Transport ◽  
Therapeutic Peptide

Novel bioemulsomes for baicalin oral lymphatic targeting: development, optimization and pharmacokinetics

Nanomedicine ◽  
2021 ◽  
Author(s):  
Samar A Rizk ◽  
Manal A Elsheikh ◽  
Yosra S R Elnaggar ◽  
Ossama Y Abdallah
Keyword(s):  
Oral Delivery ◽  
Physicochemical Characterization ◽  
Lymphatic Transport ◽  
Promising Tool ◽  
Lymphatic Pathway ◽  
In Vivo Pharmacokinetics ◽  
Lymphatic Targeting ◽  
Transport Potential

Aim: The aim of this study was to elaborate on ‘bioemulsomes,' novel biocompatible lipoprotein analogs for effective lymphatic transport of baicalin (BCL). Methods: BCL bioemulsomes were developed and optimized and in vitro physicochemical characterization performed. The bioavailability of BCL bioemulsomes compared with free BCL was investigated using in vivo pharmacokinetics studies. Finally, BCL lymphatic transport was assessed via cycloheximide blockade assay. Results: Optimized BCL-loaded nanoemulsomes showed promising in vitro characteristics that favor lymphatic targeting. In vivo pharmacokinetics showed a significant improvement in bioavailability over free BCL. A significant decrease in BCL emulsome absorption (33%) was exhibited after chemical blockage of the lymphatic pathway, confirming the lymphatic transport potential. Conclusion: Bioemulsomes could be a promising tool for bypassing BCL oral delivery hurdles as well as lymphatic transport, paving the way for potential treatment of lymphoma.

scholarly journals Use of Lipid Nanocarriers to Improve Oral Delivery of Vitamins

Nutrients ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 68 ◽  
Author(s):  
Ching-Yun Hsu ◽  
Pei-Wen Wang ◽  
Ahmed Alalaiwe ◽  
Zih-Chan Lin ◽  
Jia-You Fang
Keyword(s):  
Oral Delivery ◽  
Oral Absorption ◽  
Lymphatic Transport ◽  
Glycol Succinate ◽  
Gi Tract ◽  
Glycoprotein P ◽  
P Glycoprotein ◽  
Antioxidant Agents ◽  
Lipid Nanocarriers ◽  
Delivery Efficiency

The chemical environment and enzymes in the gastrointestinal (GI) membrane limit the oral absorption of some vitamins. The GI epithelium also contributes to the poor permeability of numerous antioxidant agents. Thus, lipophilic vitamins do not readily dissolve in the GI tract, and therefore they have low bioavailability. Nanomedicine has the potential to improve the delivery efficiency of oral vitamins. In particular, the use of lipid nanocarriers for certain vitamins that are administered orally can provide improved solubility, chemical stability, epithelium permeability and bioavailability, half-life, nidus targeting, and fewer adverse effects. These lipid nanocarriers include self-emulsifying drug delivery systems (SEDDSs), nanoemulsions, microemulsions, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs). The use of nontoxic excipients and sophisticated material engineering of lipid nanosystems allows for control of the physicochemical properties of the nanoparticles and improved GI permeation via mucosal or lymphatic transport. In this review, we highlight recent progress in the development of lipid nanocarriers for vitamin delivery. In addition, the same lipid nanocarriers used for vitamins may also be effective as carriers of vitamin derivatives, and therefore enhance their oral bioavailability. One example is the incorporation of d-α-tocopheryl polyethylene glycol succinate (TPGS) as the emulsifier in lipid nanocarriers to increase the solubility and inhibit P-glycoprotein (P-gp) efflux. We also survey the concepts and discuss the mechanisms of nanomedical techniques that are used to develop vitamin-loaded nanocarriers.

Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system

2012 ◽  
Vol 97 ◽  
pp. 109-116 ◽  
Author(s):  
Shailesh S. Chalikwar ◽  
Veena S. Belgamwar ◽  
Vivek R. Talele ◽  
Sanjay J. Surana ◽  
Mrunal U. Patil
Keyword(s):  
Transport System ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Lymphatic Transport ◽  
Solid Lipid

On the structural organization of biological pumps and channels

1984 ◽  
Vol 42 ◽  
pp. 138-141
Author(s):  
G. Zampighi ◽  
M. Kreman
Keyword(s):  
Active Transport ◽  
Transport System ◽  
Plasma Membranes ◽  
Transport Proteins ◽  
Molecular Organization ◽  
Passive Transport ◽  
Concentration Gradients ◽  
Cell Functions ◽  
Natural Concentration ◽  
Active Transport System

The plasma membranes of most animal cells contain transport proteins which function to provide passageways for the transported species across essentially impermeable lipid bilayers. The channel is a passive transport system which allows the movement of ions and low molecular weight molecules along their concentration gradients. The pump is an active transport system and can translocate cations against their natural concentration gradients. The actions and interplay of these two kinds of transport proteins control crucial cell functions such as active transport, excitability and cell communication. In this paper, we will describe and compare several features of the molecular organization of pumps and channels. As an example of an active transport system, we will discuss the structure of the sodium and potassium ion-activated triphosphatase [(Na+ +K+)-ATPase] and as an example of a passive transport system, the communicating channel of gap junctions and lens junctions.

N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery

2009 ◽  
pp. 090526005142032-9 ◽  
Author(s):  
Jinna Cao ◽  
Jukui Sun ◽  
Xiaoyu Wang ◽  
Xinran Li ◽  
Yingjie Deng
Keyword(s):  
Oral Delivery ◽  
Trimethyl Chitosan

Supplementation with beta-hydroxy-beta-methylbutyrate impacts glucose homeostasis and increases liver size in trained mice

2020 ◽  
Vol 90 (1-2) ◽  
pp. 113-123
Author(s):  
Ines Schadock ◽  
Barbara G. Freitas ◽  
Irae L. Moreira ◽  
Joao A. Rincon ◽  
Marcio Nunes Correa ◽  
...  
Keyword(s):  
Strength Training ◽  
Muscle Mass ◽  
Glucose Homeostasis ◽  
Fasting Blood Glucose ◽  
Hepatic Metabolism ◽  
Mass Gain ◽  
Trained Group ◽  
Tissue Mass ◽  
Liver Size ◽  
Intensive Training

Abstract. β-hydroxy-β-methyl butyrate (HMB) is a bioactive metabolite derived from the amino acid leucine, usually applied for muscle mass increase during physical training, as well as for muscle mass maintenance in debilitating chronic diseases. The hypothesis of the present study is that HMB is a safe supplement for muscle mass gain by strength training. Based on this, the objective was to measure changes in body composition, glucose homeostasis and hepatic metabolism of HMB supplemented mice during strength training. Two of four groups of male mice (n = 6/group) underwent an 8-week training period session (climbing stairs) with or without HMB supplementation (190 mg/kgBW per day). We observed lower body mass gain (4.9 ± 0.43% versus 1.2 ± 0.43, p < 0.001) and increased liver mass (40.9 ± 0.9 mg/gBW versus 44.8 ± 1.3, p < 0.001) in the supplemented trained group compared with the non-supplemented groups. The supplemented trained group had an increase in relative adipose tissue mass (12.4 ± 0.63 mg/gBW versus 16.1 ± 0.88, P < 0.01) compared to the non-supplemented untrained group, and an increase in fasting blood glucose (111 ± 4.58 mg/dL versus 122 ± 3.70, P < 0.05) and insulin resistance (3.79 ± 0.19 % glucose decay/min versus 2.45 ± 0.28, P < 0.05) comparing with non-supplemented trained group. Adaptive heart hypertrophy was observed only in the non-supplemented trained group (4.82 ± 0.05 mg/gBW versus 5.12 ± 0.13, P < 0.05). There was a higher hepatic insulin-like growth factor-1 expression (P = 0.002) in supplemented untrained comparing with non-supplemented untrained group. Gene expression of gluconeogenesis regulatory factors was increased by training and reduced by HMB supplementation. These results confirm that HMB supplementation associated with intensive training protocol drives changes in glucose homeostasis and liver metabolism in mice.

Sign in / Sign up

Export Citation Format

Share Document